Keith T. Flaherty, MD
Treatment with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF
-mutant advanced, unresectable or metastatic melanoma, according to updated findings from the phase III COLUMBUS trial.
The combination of encorafenib at 450 mg daily and binimetinib at 45 mg twice daily reduced the risk of death by 39% versus vemurafenib monotherapy (hazard ratio [HR], 0.61; 95% CI 0.47-0.79; P
The median overall survival was 33.6 months versus 16.9 months, respectively.
... to read the full story